SURANI R FERNANDO

Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism NEW HAVEN, CT NPI 1750355137

General Payments — all program years on this page

$15,751.99

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 895
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $544.38 across 19 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $544.3819

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Amgen Inc. $147.922
Lilly USA, LLC $88.482
Insulet Corporation $88.224
Abbott Laboratories $55.073
Novo Nordisk AS $34.212
ABBVIE INC. $33.752
Almatica Pharma Inc. $26.481
Medtronic, Inc. $24.781
IBSA Pharma Inc. $24.521
Xeris Pharmaceuticals, Inc. $20.951

By program year

Program yearAmountRecords
2018 $3,634.57248
2019 $4,475.65215
2020 $2,044.64120
2021 $2,307.28130
2022 $1,884.46113
2023 $861.0150
2024 $544.3819

Records — PY2024 (19)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1096917424 Novo Nordisk Inc $14.58 02/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097541677 Novo Nordisk Inc $19.63 08/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103723416 ABBVIE INC. $20.54 01/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103723418 ABBVIE INC. $13.21 08/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1115622086 Amgen Inc. $22.92 11/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1115622094 Amgen Inc. $125.00 09/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116794227 Insulet Corporation $21.72 05/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116794229 Insulet Corporation $22.93 02/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116813224 Insulet Corporation $21.72 07/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116827668 Insulet Corporation $21.85 11/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1119466119 Medtronic, Inc. $24.78 01/27/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1125239435 Abbott Laboratories $23.73 02/14/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1125239439 Abbott Laboratories $17.44 09/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1125239443 Abbott Laboratories $13.90 11/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135397083 Lilly USA, LLC $18.59 09/18/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1135420947 Lilly USA, LLC $69.89 12/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1137562774 Almatica Pharma LLC $26.48 06/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1142977846 IBSA Pharma Inc. $24.52 05/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1144614847 Xeris Pharmaceuticals, Inc. $20.95 12/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.